Mitochondrial Composition and Screening Method
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mitochondrial diseases, particularly those affecting the respiratory chain, are inadequate, with no validated therapies available, leading to limited options for patients who often rely on unregulated and untested vitamins and supplements for symptom management.
Innovation Solution
A composition comprising glucose, N-acetylcysteine, nicotinic acid, and optionally probucol, administered alone or in combination, is provided for treating mitochondrial diseases, along with methods for screening therapeutic agents using genetically altered C. elegans, zebrafish, and human cell models to identify effective compounds that modulate mitochondrial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If patients take vitamins and supplements on an empiric basis, then symptom management may be improved, but safety and effectiveness are compromised due to lack of regulation and standardization
Solution Approach 1:
The patent transforms the unregulated supplement approach into a regulated pharmaceutical composition by precisely defining parameters including specific compound identities (glucose, N-acetylcysteine, nicotinic acid, probucol), their concentrations (e.g., glucose 5-20 mM, N-acetylcysteine 0.1-10 mM), and administration protocols. This parameter standardization resolves the contradiction by maintaining symptom management benefits while eliminating safety risks through controlled, tested formulations.
2Reliability
If a combination of multiple compounds is used to treat mitochondrial disease, then therapeutic effectiveness is improved, but treatment complexity increases
Solution Approach 1:
The patent combines multiple therapeutic compounds (glucose, N-acetylcysteine, nicotinic acid, and probucol) into a single integrated pharmaceutical composition that addresses multiple pathological mechanisms simultaneously. This merging approach improves therapeutic effectiveness by targeting various aspects of mitochondrial dysfunction while simplifying administration, as patients receive all necessary compounds in one standardized formulation rather than managing multiple separate supplements.
3Measurement precision
If screening methods use genetically altered model organisms, then identification of therapeutic agents becomes more precise, but screening complexity and time increase
Solution Approach 1:
The patent segments the screening process into distinct hierarchical stages: primary screening in C. elegans models to identify candidate compounds, followed by secondary validation in more complex models. This segmentation allows rapid initial filtering to reduce the candidate pool, thereby maintaining high identification precision while significantly reducing overall screening time and resource requirements compared to using only complex models from the start.
Data Source
AI summary
Compositions and methods for treatment of mitochondrial respiratory chain dysfunction and other mitochondrial disorders are provided. Also disclosed are a number of screening assays having utility for the identification of agents which modulate the phenotype associated with mitochondrial respiratory chain dysfunction.